The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer.

about

The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer.

Item

http://www.wikidata.org/entity/Q38705129

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The Clinical and Economic Impa ...... ic Non-Small Cell Lung Cancer.

@en

type

Item

label

The Clinical and Economic Impa ...... ic Non-Small Cell Lung Cancer.

@en

prefLabel

The Clinical and Economic Impa ...... ic Non-Small Cell Lung Cancer.

@en

P1476

The Clinical and Economic Impa ...... ic Non-Small Cell Lung Cancer.

@en

P2093

John F Palma

http://www.w3.org/2001/XMLSchema#string

Mindy M Cheng

http://www.w3.org/2001/XMLSchema#string

Nick Poulios

http://www.w3.org/2001/XMLSchema#string

Oliver Liesenfeld

http://www.w3.org/2001/XMLSchema#string

Sidney Scudder

http://www.w3.org/2001/XMLSchema#string

P2860

The average body surface area of adult cancer patients in the UK: a multicentre retrospective study

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study.

Diagnostic errors--the next frontier for patient safety.

Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.

P31

scholarly article

P356

10.3390/JPM7030005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Oliver Liesenfeld

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28657610

http://www.w3.org/2001/XMLSchema#string

P932

5618152

http://www.w3.org/2001/XMLSchema#string